T‐Cell Response After SARS ‐ CoV ‐2 Vaccination in Patients With Hematological Malignancy
European Journal of Haematology · 30.10.2026
DOI: 10.1111/ejh.70345 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 30.10.2026. Verfasst von L S Boerenkamp und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+…. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Patients with hematologic malignancies (HM) often mount poor humoral responses to SARS‐CoV‐2 vaccination due to their immunocompromised status. Protection against severe COVID‐19 is strongly related to cellular immunity, yet vaccine‐induced T‐cell responses remain incompletely characterized. We conducted a systematic review of 87 studies assessing vaccine‐induced T‐cell response rates in HM. Across HM subtypes, 75%–87% of studies reported T‐cell response rates of at least 50%. Active disease was associated with reduced T‐cell responses. These findings indicate that SARS‐CoV‐2 vaccination can elicit cellular immunity in HM patients, including those receiving immunosuppressive therapy, supporting continued vaccination strategies even when humoral responses are suboptimal.
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hematology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands.
- Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center+, Maastricht, the Netherlands.
- Experimental Hematology, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Transplantation Immunology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands.
ORCID-Profile: L S Boerenkamp, N Scheffers, G N Y van Gorkom, C R Pothast, M H M Heemskerk, L Wieten, C H M J Van Elssen
Zitieren
APA
Boerenkamp, L. S., Scheffers, N., Brandts, L., van Gorkom, G. N. Y., Pothast, C. R., Heemskerk, M. H. M., Wieten, L., & Van Elssen, C. H. M. J. (2026). T‐Cell Response After SARS ‐ CoV ‐2 Vaccination in Patients With Hematological Malignancy. European Journal of Haematology. https://doi.org/10.1111/ejh.70345
Vancouver
Boerenkamp LS, Scheffers N, Brandts L, van Gorkom GNY, Pothast CR, Heemskerk MHM, et al. T‐Cell Response After SARS ‐ CoV ‐2 Vaccination in Patients With Hematological Malignancy. European Journal of Haematology. 2026. doi:10.1111/ejh.70345
BibTeX
@article{Boerenkamp2026,
author = {Boerenkamp, L S and Scheffers, N and Brandts, L and van Gorkom, G N Y and Pothast, C R and Heemskerk, M H M and Wieten, L and Van Elssen, C H M J},
title = {T‐Cell Response After SARS ‐ CoV ‐2 Vaccination in Patients With Hematological Malignancy},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70345}
}
EUVIMED